Sees FY23 revenue $720M-$750M, consensus $724.97M. Adjusted EPS is expected to improve through 2023, reaching positive adjusted profitability and operating cash flow in Q4.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MYGN:
- Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
- Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
- Myriad Genetics to Participate in Upcoming Healthcare Conferences
- Myriad Genetics highlights 2022 research findings
- Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing